Cancer is responsible for the highest disease burden globally [9], and MASTL is implicated as a poor prognostic factor in several of the most lethal cancer subtypes, including breast [10,11], gastric [12], colon [13], liver, non-small-cell lung cancer (NSCLC), and ovarian (Figure 3). Here, MASTL is linked to non-small cell lung carcinoma.